FindTrial
Sign In

Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects

A Two-arm, Open-label, Single-sequence, Multiple Oral Dosings, Crossover Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of DWC202313 and DWC202314 in Healthy Adult Volunteers

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06119958
Enrollment
32
Registered
2023-11-07
Start date
2023-10-27
Completion date
2023-12-31
Last updated
2023-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Drug Interaction

Brief summary

This is A two-arm, open-label, single-sequence, multiple oral dosings, crossover study to evaluate the safety and the pharmacokinetic interaction of DWC202313 and DWC202314 in healthy adult volunteers.

Interventions

DRUGDWC202313

Experimental Drug 1

DRUGDWC202314

Experimental Drug 2

Sponsors

Daewoong Pharmaceutical Co. LTD.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* over 19 year old

Exclusion criteria

* Galactose intolerance * Lapp lactase deficiency

Design outcomes

Primary

MeasureTime frame
Cmax,ss of DWC202313 and DWC202314Up to 14 days
AUCt,ss of DWC202313 and DWC202314Up to 14 days

Secondary

MeasureTime frame
t1/2 of DWC202313 and DWC202314Up to 14 days
CLss/F of DWC202313 and DWC202314Up to 14 days
Tmax,ss of DWC202313 and DWC202314Up to 14 days
PTF of DWC202313 and DWC202314Up to 14 days
Vdss/F of DWC202313 and DWC202314Up to 14 days
Cmin,ss of DWC202313 and DWC202314Up to 14 days

Countries

South Korea

Contacts

Primary ContactSeung-Hyun Kang, MD, Ph D
juspa@newyjh.com070-4665-9490

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026